

## Effects of *Gymnema lactiferum* leaves on glycemic and lipidemic status in type 2 diabetes subjects

Thushari Bandara<sup>1</sup>, Begum Rokeya<sup>2</sup>, Sakina Khan<sup>2</sup>, Liaquat Ali<sup>2</sup>, Sagarika Ekanayake<sup>1</sup>, Errol.R.Jansz<sup>1</sup>, Kandiah Balasubramaniam<sup>3</sup>

<sup>1</sup>Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka; <sup>2</sup>Biomedical Research Group, BIRDEM, K.N. Islam Avenue, Dhaka, Bangladesh; <sup>3</sup>Biotech (Pvt) Ltd, Jaffna, Sri Lanka.

### Article Info

Received: 3 October 2008  
Accepted: 22 April 2009  
Available Online: 23 April 2009

#### Keywords:

Blood glucose  
Cholesterol  
*Gymnema lactiferum*  
HbA<sub>1c</sub>  
LDL  
Type 2 diabetics

Number of Tables: 4  
Number of Refs: 17

Correspondence: BR

e-mail: b\_rokeya@yahoo.com

### Abstract

The diabetic patients in Sri Lanka use *G. lactiferum* leaves as a treatment for diabetes. However, scientific data is not available on this plant. A clinical trial was conducted including 26, type 2 diabetic patients with hypercholesterolemia. The treatment group received a suspension of *G. lactiferum* leaf powder twice daily for four weeks. Blood parameters of both groups (treated and control) were determined at the beginning and the end of the study period. Study indicates significant effects on FBS (p=0.002), cholesterol (p=0.004), and LDL lowering (p=0.023) and a significant postprandial glucose lowering effect (p=0.026 for 60 min and p=0.022 for 120 min, after four weeks). In spite of the short study period, a significant reduction (p=0.012) in HbA<sub>1c</sub> levels was also observed.

### Introduction

*Gymnema lactiferum* var. *lactiferum* is a woody branched climber which belongs to the family *Asclapiadaceae*. It is known as "Kurincha" in Sinhala and "Kshirakali" in Sanskrit. The plant is distributed in Assam, Malay Peninsula, MalayDassanayakesia and Sri Lanka (Dassanayake and Fosberg, 1983).

The leaves of *G. lactiferum* are used as salads, curries and in herbal gruels. It possess cooling, anabolic, rehydrating, spermiogenic (Ayurveda Pharmacopia, 1961) and wormicide properties. *G. lactiferum* leaves have been used as a supportive treatment for diabetes by people in Jaffna, Sri Lanka for several decades. The present report describes the effects of this plant material on glycemic and lipidemic status of type 2 diabetic patients. No scientific studies on this plant have been found in the literature.

### Materials and Methods

*Identification, collection and preparation of the leaf powder:* The plant was identified at the National Herbarium,

Sri Lanka. Plants were grown in Jaffna, Sri Lanka. They were grown with organic composts avoiding the use of synthetic fertilizers, insecticides and fungicides. After washing, mature leaves were dried hygienically in sunlight for 4-5 days within an enclosure covered with a glass roof. After grinding and sieving, the leaf powder was packed into 100 g packets.

*Selection of patients:* Patients were selected from the out-patient wing of the Bangladesh Institute for Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders (BIRDEM), Dhaka. Ethical clearance was obtained from the ethical review committee, BIRDEM, Bangladesh

Diabetes was diagnosed according to WHO (1999) criteria. Hypercholesterolemia was detected according to the lipid profile levels of the patients. Type 2 diabetic patients (n=12, age 30-60 years) with hypercholesterolemia were included in the test group. Patients of more than 60 years of age, suffering from serious recurrent illnesses, hypertension or any other endocrinological diseases were excluded from the study. Patients with a serum creatinine level of more



than 1.7 mg/dL and the patients on any dislipidemic drug were also excluded. Another group of type 2 diabetics (n=14) with hypercholesterolemia served as the control group.

Informed consent of each patient was obtained after explaining the purpose and the procedure of the study. Patients had to fulfill four visits (one visit/week) during the study period. Body weights were recorded on the day zero and on the 29<sup>th</sup> day. Patients complaints (if any) on gastric discomfort, generalized weakness, headache, vertigo, twingling sensation of the limbs, nausea, drowsiness, dryness of mouth, anorexia and flatulence etc. were recorded during each visit.

**Sample collection:** Fasting blood samples of 10 mL were drawn from the antecubital vein (zero hour). The test group patients received a suspension of *G. lactiferum* leaf powder (3.5 g dissolved in 30 mL of water) before their breakfast which was supplied according to their diet charts. Blood samples were drawn at 1 hour and 2 hour time intervals. Patients were provided with individual leaf powder doses (wrapped in a paper pack and sealed in a polythene bag) for the rest of the week. They were requested to take the preparation just before breakfast and just before dinner each day for one month.

Fasting blood (1 mL) was transferred in an EDTA containing tube to be used in the determination of HbA<sub>1C</sub>. The rest of the blood was centrifuged at 4000 rpm for 10 min and serum was transferred to new Eppendorff tubes and re-centrifuged at 3,000 rpm for 5 min and the supernatant was separated. Serum samples were analyzed for fasting glucose, serum total cholesterol, TG, HDL-cholesterol, SGPT and creatinine. The same procedure was followed on the last day where the above biochemical parameters were tested.

**Estimation of blood parameters:** Serum glucose levels were estimated using GOD POD Enzymatic kit (Randox Laboratories Ltd, UK) using Auto analyzer Auto Lab (Kunst et al., 1984). Serum total cholesterol levels were estimated using CHOD-PAP (Randox Laboratories Ltd, UK) reagent kit (Allain et al., 1974). High-density lipoproteins were separated from chylomicrons, VLDL and LDL by the addition of precipitating reagent (phosphotungstic-magnesium chloride) to serum (Hainline et al., 1980). After centrifugation, the cholesterol content of HDL fraction which remains in the supernatant was determined by the enzymatic colorimetric method using the total cholesterol, CHOD-PAP kit. Serum TG was estimated by enzymatic GPO-PAP (Randox Laboratories Ltd, UK) kit (Tietz, 1990) and serum LDL-cholesterol was calculated by using the Friedewald formula (Friedewald et al., 1972). The serum alanine aminotransferase (SGPT) levels were estimated by

using ALT (GPT) Opt. (Randox Laboratories Ltd, UK) kit (International Federation of Clinical Chemistry, 1980) using the Auto analyzer, Auto Lab. Serum creatinine levels were measured by the alkaline picric acid colorimetric method (Toro and Ackermann, 1975). The level of HbA<sub>1C</sub> (in whole blood) was analyzed by using VARIANT Hemoglobin A<sub>1C</sub> program (Mayer and Freedman, 1983).

**Statistical analysis:** Results are presented as mean  $\pm$  standard deviation (SD). Groups of data were compared using student t-test. Differences were considered significant at  $p < 0.05$ .

## Results

All 26 patients enrolled in the study had similar baseline characteristics (Table I). All patients were on oral hypoglycemic agents but any dose adjustments were not made during the study. Since it was not possible to conduct a double blind experiment, the patients were aware of who were the tests and who were the controls. The patients were expected to continue their normal dietary habits. However, control patients were reported to follow dietary controls. Despite this, *G. lactiferum* therapy indicated many beneficial effects on the glycemic and lipidemic status of the patients.

The body weight of the *Gymnema* treated group had reduced by 0.74% in comparison to their day zero values ( $66.92 \pm 12.11$  Vs  $67.42 \pm 12.57$ ,  $p=0.089$ ) and 0.39% reduction of the same parameter was observed in the control group ( $62.57 \pm 10.84$  Vs  $62.87 \pm 11.31$ ,  $p=0.204$ ). However, those changes were insignificant.

The effect of *G. lactiferum* leaf powder on fasting serum glucose levels has been shown in Table II. A gradual reduction was observed in the *Gymnema*-treated group. There was a 10.7% reduction on day 15. The reduction became significant ( $p=0.002$ ) on day 29 (with an 18.15% reduction).

**Table I:** Baseline characteristic of the patients

Demographics	Gymnema lactiferum (n=12)	Control (n=14)	p value
Age in years	47 $\pm$ 10	45 $\pm$ 11	0.505
No. of males	7	5	
Mean Body Mass Index (kg/m <sup>2</sup> $\pm$ SD)	26.84 $\pm$ 6.25	25.36 $\pm$ 2.94	0.464
Mean HbA <sub>1C</sub> (% $\pm$ SD)	7.91 $\pm$ 1.72	7.58 $\pm$ 1.68	0.626
Mean FBS (mmol/L)	8.05 $\pm$ 1.79	7.47 $\pm$ 1.84	0.426
Mean total cholesterol (mg/dL)	235.83 $\pm$ 26.37	235.71 $\pm$ 32.86	0.992
Mean creatinine (mg/dL)	1.08 $\pm$ 0.15	1.04 $\pm$ 0.09	0.396
Mean SGPT (IU/L)	28.92 $\pm$ 12.16	25.64 $\pm$ 13.40	0.523

**Table II:** Effect of *G. lactiferum* leaf powder on fasting serum glucose levels of type 2 diabetes patients

Group	Fasting serum glucose levels (mmol/L) Mean $\pm$ SD		
	Day 0	Day 15	Day 29
Control (n=14)	7.47 $\pm$ 1.84	7.12 $\pm$ 1.61	6.84 $\pm$ 2.16
Gymnema treated (n=12)	8.05 $\pm$ 1.79	7.19 $\pm$ 1.56	6.59* $\pm$ 1.28

\*p=0.002 in comparison to day zero

As shown in Table III there were significant reductions (p=0.026 for 60 min and p=0.022 for 120 min) in postprandial serum glucose levels in the *Gymnema*-treated group on day 29 in comparison to day zero.

Though the study period was four weeks, there was a significant (p=0.012) reduction (11.6%) in HbA<sub>1c</sub> levels in comparison to the day zero values in the *Gymnema*-treated group (6.99  $\pm$  0.93 Vs 7.91  $\pm$  1.72). However, such a reduction was not observed in the control group (7.39  $\pm$  1.24 Vs 7.58  $\pm$  1.68, p=0.316).

**Table III:** Effect of *G. lactiferum* leaf powder on postprandial blood glucose levels of type 2 diabetes patients

Group	Serum glucose levels (mmol/L) Mean $\pm$ SD			
	After 60 min		After 120 min	
	Day zero	Day 29	Day zero	Day 29
Control (n=14)	12.44 $\pm$ 2.98	11.76 $\pm$ 3.32	12.53 $\pm$ 3.59	11.17 $\pm$ 3.91
Gymnema treated (n=12)	13.81 $\pm$ 2.72	11.78 <sup>1</sup> $\pm$ 1.66	14.85 $\pm$ 3.03	12.35 <sup>2</sup> $\pm$ 2.87

<sup>1</sup>p=0.026, <sup>2</sup>p=0.022 in comparison to day zero

The serum total cholesterol levels of the *Gymnema*-treated group reduced significantly (p=0.004) by the 29<sup>th</sup> day (Table IV). There was a 12.3% reduction in comparison to the day zero value. However, the serum HDL levels remained steady (p=0.417) throughout the study period. As shown in Table IV, there was a significant reduction (p=0.023) in the serum LDL levels in the *Gymnema*-treated group on day 29 in comparison to day zero. The reduction was 15.5%. However, this therapy did not produce any significant reduction (p=0.380) in serum TG levels (Table IV).

**Table IV:** Effect of *G. lactiferum* leaf powder on serum total cholesterol, HDL, LDL and TG levels of type 2 diabetes patients

Group	Serum levels (mg/dL) (Mean $\pm$ SD)							
	Total Cholesterol		HDL		LDL		TG	
	Day 0	Day 29	Day 0	Day 29	Day 0	Day 29	Day 0	Day 29
Control (n=14)	235.71 $\pm$ 32.86	218.29 $\pm$ 38.36	37.54 $\pm$ 7.40	35.17 $\pm$ 8.23	155 $\pm$ 36	140 $\pm$ 44	218.14 $\pm$ 104.19	213.93 $\pm$ 99.88
Gymnema treated (n=12)	235.83 $\pm$ 26.37	206.75 <sup>1</sup> $\pm$ 35.74	36.82 $\pm$ 7.44	34.67 $\pm$ 6.15	155 $\pm$ 20	131 <sup>2</sup> $\pm$ 33	222.75 $\pm$ 81.10	207.17 $\pm$ 105.41

\*p=0.004, <sup>1</sup>p=0.023 (in comparison to day zero)

Serum ALT (p=0.261) and creatinine (p=0.797) levels remained steady in both groups throughout the study period. On the day zero the serum mean ALT level (U/l) in the treated group was 28.92  $\pm$  12.16 and on the day 29 it was 31.67  $\pm$  15.01. In the control group the relevant values of this parameter was 25.64  $\pm$  13.40 Vs 28.57  $\pm$  15.25. The mean serum creatinine level (mg/dL) of the treated group was 1.08  $\pm$  0.15 Vs 1.09  $\pm$  0.15, whereas in the control group this was 1.04  $\pm$  0.09 Vs 1.05  $\pm$  0.08.

## Discussion

Although *G. lactiferum* leaf powder did not produce any acute blood glucose lowering effect, its chronic consumption led to a gradual reduction in FBS and after four weeks of treatment the reduction was significant (p=0.002). The patients of both groups were on their conventional oral hypoglycemic drugs. Therefore this indicates the added advantage of *G. lactiferum* therapy on the patient's glycemic status. Though the postprandial blood glucose (PPG) levels did not show any significant reduction in the acute experiments, after treating the patients with leaf powder for four weeks their PPG levels went down significantly in comparison to day zero levels. This suggests that the leaf powder could overcome postprandial hyperglycemia which is one of the major causes for the initiation and progression of many diabetic complications. Further the chronic consumption of leaf powder produced a significant decline (p=0.004) in serum total cholesterol levels and serum LDL levels (p=0.023). However, there was no significant changes in serum HDL (p=0.417) and TG (p=0.380). The insignificant serum ALT (p=0.261) and creatinine (p=0.797) levels indicated that there was no detrimental effects on the liver and kidneys of the patients.

The body weights of patients' did not show significant changes (p=0.089) throughout the study period. No complaints were made by the patients while consuming the leaf powder. Some patients had a history of generalized weakness, gastric discomfort and constipation prior to the treatment. All the above complaints were alleviated and gradually subsided while being fed on the leaf powder.

Dyslipidemia plays an important role in long term complications of diabetes. Therefore correction of dyslipidemia is essential. Modern lipid lowering agents (like atorvastatin, fluvastatin, lovastatin etc.) are not only expensive; they can lead to hepatic dysfunction, renal insufficiency, hypothyroidism etc. (Stancu and Sina, 2001). Conversely, *G. lactiferum* leaves, as natural products are comparatively cheap and easily reachable to common people. As it has been shown that oral administration of *G. lactiferum* to type 2 subjects for four weeks did not produce any toxic effect, it may be hypothesized that *G. lactiferum* might depress hepatic activities of lipogenic and cholesterologenic enzymes. This might also happen due to increased fecal excretion of cholesterol by *G. lactiferum* leaves. A significant decrease in cholesterol level in patients with oral consumption of *G. lactiferum* leaves, suggests the atheroprotective potential of this herb.

Though the exact mechanism is not yet clear, it seems that the decrease in atherogenic LDL level could have resulted from the antioxidant effect of the leaves of *G. lactiferum*, whose phytochemical components may include flavonoids. The effect of flavonoids and flavonoid rich extract on reducing lipid levels effectively has been documented in many studies (Asha et al., 2001; Sudheesh et al., 1997; Valsa et al., 1995; Imai and Nakachi, 1995; Kono et al., 1992; Matsude et al., 1986). Therefore, the obtained lipid lowering effect of *G. lactiferum* may be, due to the combination of all these mechanisms.

---

#### Acknowledgements

The financial support given by IPICS (International Program in Chemical Sciences, Sweden) and ANRAP (Asian Network of Research on Antidiabetic Plants) is gratefully acknowledged. Authors are grateful to the technical staff of the Research Division, BIRDEM for their help.

---

#### References

- Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Clin Chem. 1974; 20: 470-75.
- Asha SK, Anila L, Vijayalakshmi NR. Flavonoids from *Garcinia cambogia* lower lipid levels in hypercholesterolemic rats. Food Chem. 2001; 72: 289-94. [doi:10.1016/S0308-8146\(00\)00225-9](https://doi.org/10.1016/S0308-8146(00)00225-9)
- Ayurveda Pharmacopoeia Vol. I. part 3. Published by the Department of Ayurveda, Colombo, Sri Lanka; 1961, p 114.
- Dassanayake MD, Fosberg FR. A revised hand book to the flora of Ceylon. Vol. IV. New Delhi, Amering Publishers, 1983, pp 97-98.
- Friedewald WT, Levy RI, Fedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
- Hainline AJR, Cooper GR, Olansky AS. CDC Survey of high-density lipoprotein cholesterol measurement: A report. Atlanta Lipid Standardization Program. Center for Disease Control; 1980, p 3.
- Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver disease. Bri Med J. 1995; 310: 693-96.
- International Federation of Clinical Chemistry, Scientific Committee. J Clin Chem Clin Biochem. 1980; 18: 521-34.
- Kono S, Shinchi K, Ikeda N, Yanai F, Imanichi K. Green tea consumption and serum lipid profiles: a cross sectional study in Northern Kyushu, Japan. Prev Med. 1992; 21: 526-31. [doi:10.1016/0091-7435\(92\)90060-U](https://doi.org/10.1016/0091-7435(92)90060-U)
- Kunst A, Draeger B, Ziegenhorn J. Methods of enzymatic analysis. Vol. 6. Weinheim, W Germany, Deerfield Beach, 1984, pp 178-85.
- Matsuda H, Chisaka T, Kubumura Y, Yamahara J, Savada T, Fujima H, Kimura H. Effect of crude drugs on experimental hypercholesterolemia-1-tea and its active principles. J Ethnopharmacol. 1986; 17: 213-24. [doi:10.1016/0378-8741\(86\)90110-8](https://doi.org/10.1016/0378-8741(86)90110-8)
- Mayer TK, Freedman ZR. Protein glycosylation in diabetes mellitus: A review of laboratory measurements and of their clinical utility. Clin Chem Acta 1983; 127: 147-84. [http://dx.doi.org/10.1016/S0009-8981\(83\)80002-3](http://dx.doi.org/10.1016/S0009-8981(83)80002-3)
- Stancu C, Sina A. Statin: Mechanism of action and effects. Bucharesh, Romania, Nicolas Simoinesae Institute of Cellular Biology and Pathology, 2001.
- Sudheesh S, Presanna Kumar G, Vijayakumar S, Vijayalakshmi NR. Hypolipidemic effect of flavonoids from *solanum melongena*. Plant Foods Human Nutr. 1997; 51: 321-30. [doi:10.1023/A:1007965927434](https://doi.org/10.1023/A:1007965927434)
- Tietz NW. Clinical guide to Laboratory tests. 2<sup>nd</sup> ed. Philadelphia, USA, W.B. Saunders Company, 1990, pp 554-56.
- Toro G, Ackermann PG. Practical clinical chemistry. Boston, Little Brown and Co, 1975, p 154.
- Valsa AK, Ushakumary B, Vijayalakshmi MR. Effect of catechin on lipid metabolism. J Clin Biochem Nutr. 1995; 19: 175-82.
-